First, the differences in efficacy of CD19 and CD20 targeting treatments could indirectly hint at the role of CD20+ T cells in the pathogenesis or disease course of MS as these cells do not express CD19 on their cell surface and are hence not depleted with anti-CD19 mabs [92]. This evidence concerns the gene CD19 and myeloid sarcoma.